Table 3.
Clinical characteristics of respective training and test study populations
| Training set n = 158 | Age (years) Median (95% CI) | Gender Male: Female | CA19-9 (KU/L) Median (95% CI) | Bilirubin (μmol/L) Median (95% CI) |
|---|---|---|---|---|
|
PDAC (n = 84) |
66 (64.0-69.0) |
47:37 |
137.5 (62.0-161.4) |
31 (24.5-54.3) |
|
CP (n = 32) |
53 (48.0-58.6) |
20:12 |
24.5 (11.0-41.0) |
7 (6.0-10.0) |
|
BBO (n = 13) |
72 (60.7-77.4) |
11:2 |
89 (13.5-228.3) |
69 (11.0-108.6) |
|
HC (n = 29) |
44 (29.9-54.0) |
14:15 |
4 (2.0-6.0) |
NA |
|
Test Set n = 83 |
Age (years) Median (95%CI) |
Gender Male: Female |
CA19-9 (KU/L) Median (95%CI) |
Bilirubin (μmol/L) Median (95% CI) |
|
PDAC (n = 43) |
68 (64.2-71.8) |
24:19 |
116 (54.9-164.4) |
51 (19.6-114.0) |
|
CP (n = 17) |
53 (45.1-62.0) |
10:7 |
12 (8.0-24.9) |
6 (5.0-10.0) |
|
BBO (n = 7) |
64 (38.4-78.5) |
3:4 |
37 (4.5-181.3) |
100 (44.9-374.9) |
| HC (n = 16) | 56.5 (36.7-62.1) | 9:7 | 3 (2.6-8.4) | NA |
PDAC = Cancer, CP = Chronic Pancreatitis, BBO = Benign Biliary Obstruction, HC = Healthy Controls.